CDUX
LIVE

Serial Number

99221582

Owner

Avidity Biosciences, Inc.

Attorney

Aaron D. Hendelman

Filing Date

Jun 6, 2025

Add to watchlist:

No watchlists yet
View on USPTO

CDUX Trademark

Serial Number: 99221582

CDUX is a trademark filed by Avidity Biosciences, Inc. on June 6, 2025. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

Avidity Biosciences, Inc. (41 trademarks)

10578 Science Drive, Suite 125
San Diego, CA 92121

Entity Type: 03

Trademark Details

Filing Date

June 6, 2025

Registration Date

Not Registered

Published for Opposition

November 25, 2025

Goods & Services

Medical and scientific research, namely, conducting clinical trials for others; providing medical and scientific research information in the fields of pharmaceuticals, biotechnology, and clinical trials; pharmaceutical research and development; pharmaceutical products development; research and development in the field of biotechnology

Therapeutic pharmaceuticals in the nature of oligonucleotide-conjugate based therapies, oligonucleotide-antibody conjugate based therapies, and oligonucleotide-antibody fragment conjugate based therapies for the treatment of and prevention of musculoskeletal, neuromuscular, rare muscle diseases, cardiomyopathies, heart muscle diseases, muscular dystrophies, and muscle atrophy related diseases and disorders; pharmaceutical preparations for the treatment and prevention of viral, metabolic, endocrine, musculoskeletal, autoimmune, cardiovascular, cardiopulmonary, neuromuscular, rare muscle diseases, cardiomyopathies, heart muscle diseases, muscular dystrophies, muscle atrophy, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, neurodegenerative, gastrointestinal, hormonal, dermatological, psychiatric, genetic, and immune system related diseases and disorders; pharmaceutical preparations for the treatment and prevention of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; pharmaceutical preparations, namely, anti-infective preparations, medicated dermatological preparations and smoking cessation preparations; therapeutic pharmaceutical for the treatment and prevention of viral, metabolic, endocrine, musculoskeletal, autoimmune, cardiovascular, cardiopulmonary, neuromuscular, rare muscle diseases, cardiomyopathies, heart muscle diseases, muscular dystrophies, muscle atrophy, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, neurodegenerative, gastrointestinal, hormonal, dermatological, psychiatric, genetic, and immune system related diseases and disorders; therapeutic pharmaceuticals for the treatment and prevention of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 7, 2026 EXRA
SOU EXTENSION 1 GRANTED
May 6, 2026 EX1G
SOU EXTENSION 1 FILED
May 6, 2026 EXT1
SOU TEAS EXTENSION RECEIVED
May 6, 2026 EEXT
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Mar 5, 2026 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Mar 5, 2026 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Mar 5, 2026 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Mar 5, 2026 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Mar 5, 2026 COAR
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jan 20, 2026 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Nov 25, 2025 NPUB
PUBLISHED FOR OPPOSITION
Nov 25, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 19, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Oct 29, 2025 CNSA
ASSIGNED TO EXAMINER
Oct 27, 2025 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 13, 2025 NWOS
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Sep 5, 2025 TCCA
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Sep 5, 2025 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Sep 5, 2025 COAR
APPLICATION FILING RECEIPT MAILED
Jun 6, 2025 MAFR
NEW APPLICATION ENTERED
Jun 6, 2025 NWAP